NCT04733443 - The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis | Biotech Hunter

Enrollment

310

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

January 18, 2023

Study Completion Date

February 18, 2025

Conditions

Coronary Artery Disease

Interventions

DEVICE

Biolimus

140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group

DEVICE

SeQuent® Please Neo

140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group

Trial Locations (1)

The First Medical Center of the PLA General Hospital, Beijing